Table 2.
Demographics for Enrolled Subjects Receiving at Least One Dose
| CMV gB + MF59 (N=195) | Placebo (N=207) | All (N=402) | P-value | |
|---|---|---|---|---|
| N Subjects in Safety Population | 195 | 207 | 402 | |
| Age at Vaccination(years) | 0.1890 [1] | |||
| Mean (SD) | 14.7 (1.64) | 14.5 (1.60) | 14.6 (1.62) | |
| Median | 15.0 | 15.0 | 15.0 | |
| Min, Max | 12, 18 | 12, 17 | 12, 18 | |
| Q1 : Q3 | 13.0 : 16.0 | 13.0 : 16.0 | 13.0 : 16.0 | |
| Age Category at Vaccination, n (%) | 0.5860 [2] | |||
| 12–15 years old | 124 (64) | 137 (66) | 261 (65) | |
| > 15 years old | 71 (36) | 70 (34) | 141 (35) | |
| Ethnic origin, n (%) | 0.5956 [2] | |||
| Hispanic or Latino | 22 (11) | 20 (10) | 42 (10) | |
| Not Hispanic or Latino | 173 (89) | 187 (90) | 360 (90) | |
| Race, n (%) | 0.2494 [2] | |||
| Black | 77 (39) | 88 (43) | 165 (41) | |
| Caucasian | 103 (53) | 95 (46) | 198 (49) | |
| Other | 15 (8) | 24 (12) | 39 (10) |
P-value is from an analysis of variance with treatment as an effect in the model.
P-value is from a Chi-square test.